Mannitol 25 % Injection Fresenius 50 ml Solution for injection.
PDF Leaflet Revision Date: 07 April 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prophylaxis against acute renal failure and reduction of intracranial pressure.
Dosage (summary)
50 to 200 g over 24 hours; test dose of 200 mg/kg for oliguria.
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- Increased clearance of lithium
- Potentiation with other diuretics
Contraindications
- Hypersensitivity to mannitol
- Severe renal disease
- Pulmonary congestion
- Intracranial bleeding
Common side effects
- Headache
- Dizziness
- Nausea
- Dehydration
- Hyponatraemia
Counselling Points
- Monitor fluid and electrolyte balance
- Do not mix with blood
- Warm before use to dissolve crystals
Serious warnings
- Risk of CNS toxicity
- Risk of renal complications
- Risk of hypervolaemia
Important Disclaimer
The Mannitol 25 % Injection Fresenius 50 ml Solution for injection. professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
